PTC Therapeutics
PTCT
196 hedge funds and large institutions have $3.34B invested in PTC Therapeutics in 2020 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 66 increasing their positions, 73 reducing their positions, and 30 closing their positions.
53% more call options, than puts
Call options by funds: $15.6M | Put options by funds: $10.2M
2.17% more ownership
Funds ownership: 103.44% → 105.61% (+2.2%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
4% less capital invested
Capital invested by funds: $3.47B → $3.34B (-$131M)
10% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 73
3% less funds holding
Funds holding: 202 → 196 (-6)
20% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$169M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$71.3M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$13.2M |
| 4 |
AC
Armistice Capital
New York
|
+$11M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$9.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$25M |
| 2 |
Goldman Sachs
New York
|
-$23.4M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$16.7M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$16.5M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$14.4M |
PTCT Hedge Fund Activity: Q3 2020 in Review
196 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2020, worth a combined $3.34B — down 3.8% from $3.47B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of PTCT and 24 opened new positions — a net loss of 6 holders — while 73 trimmed existing stakes and 66 added.
The largest buyer was Fidelity Investments, adding an estimated $169M. The largest seller was Artisan Partners, exiting entirely with an estimated $25M sold.
- 196 institutional investors held PTC Therapeutics (PTCT) as of Q3 2020, down from 202 in Q2 2020.
- Funds reported $3.34B of PTC Therapeutics stock for Q3 2020, down 3.8% quarter-over-quarter.
- 24 funds opened new PTC Therapeutics positions in Q3 2020 and 30 closed out, a net change of -6 holders.
- The largest PTC Therapeutics buyer in Q3 2020 was Fidelity Investments, an estimated $169M added.
- The largest PTC Therapeutics seller in Q3 2020 was Artisan Partners, an estimated $25M sold.
Based on aggregated 13F filings for Q3 2020.